Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $17.4352W HIGH $31.73
Volume
2.02 M
Value Traded
26.21 M
Short % Float
14.45%
Days to Cover
9.7
-5.01%Week
-28.3%1 Month
-34.9%3 Month
-27.88%6 Month
-10.78%5 Year
+17.15%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.34 B
EPS (TTM)
-3.61
P/E Ratio
-
Ent. Value
1.67 B
Total Shares
127.33 M
Float Shares
85.50 M
Insiders
32.85%
Institutions
68.71%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
RCUS Catalyst Timeline
Dated clinical, regulatory and corporate events for Arcus Biosciences, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Arcus Biosciences, Inc.
314Total events
17Upcoming
85Tier-1 (high impact)
2018 to 2028Coverage
Upcoming catalysts 2
Event history 50
▼Equity OfferingCorporate
Pricing of $250 million public offering of common stock at $17.50 per share
▼Equity OfferingCorporate
Arcus Biosciences commences underwritten public offering of common stock
▲Additional DatacasdatifanClinical Data
New ARC-20 data across 1L, 2L and late-line cohorts presented at investor event
clear cell renal cell carcinoma (ccRCC)source ↗
●R&D DayPresentation
Arcus hosting in-person and virtual investor event in New York to review casdatifan data
●Trial InitiationAB102Trial
First-in-human healthy volunteer study of AB102 expected to initiate this month
atopic dermatitis and chronic spontaneous urticariasource ↗
▲Partnership / LicenseCorporate
Clinical trial collaboration to evaluate casdatifan + ivonescimab in ccRCC
clear cell renal cell carcinoma (ccRCC)source ↗
◆Trial InitiationcasdatifanTrial
Planned initiation of casdatifan + ivonescimab cohort in ARC-20
clear cell renal cell carcinoma (ccRCC)source ↗
◆PublicationcasdatifanPresentation
Research published in Nature linking clinical activity with HIF-2a biology in advanced kidney cancer patients treated with Casdatifan
advanced kidney cancersource ↗
▲Milestone PaymentcasdatifanCorporate
Arcus to receive $15M milestone payment from Taiho triggered by PEAK-1 enrollment in Japan
clear cell renal cell carcinomasource ↗
▲PublicationcasdatifanPresentation
ARC-20 casdatifan monotherapy results published in Nature
advanced clear cell renal cell carcinomasource ↗
◆Oral PresentationPresentation
Participation in Goldman Sachs 47th Annual Global Healthcare Conference
▲Partnership / LicensecasdatifanCorporate
Clinical trial collaboration and supply agreement to evaluate casdatifan in combination with PD-L1/VEGF-A bispecific immunomodulator
kidney cancersource ↗
▲EU Orphan DesignationQuemliclustatEx-US Regulatory
EMA granted orphan drug designation to quemliclustat for pancreatic cancer
pancreatic cancersource ↗
●Oral PresentationAB102Presentation
Preclinical data for AB102 presented in oral presentation at Society for Investigative Dermatology Annual Meeting
atopic dermatitis and chronic spontaneous urticariasource ↗
◆Topline ReadoutcasdatifanClinical Data
More mature data from casdatifan+cabozantinib cohort expected in mid-2026
IO-experienced ccRCCsource ↗
◆Poster PresentationcasdatifanPresentation
Poster presentation of new efficacy and biomarker data for casdatifan at ASCO GU 2026
metastatic clear cell renal cell carcinomasource ↗
▲Oral PresentationcasdatifanPresentation
Updated data from ARC-20 dose-escalation and expansion cohorts presented at ASCO GU
clear cell renal cell carcinoma (ccRCC)source ↗
▼Trial DiscontinuedDomvanalimabDiscontinuedTrial
Discontinuation of Phase 3 studies of domvanalimab plus zimberelimab in NSCLC due to futility
non-small cell lung cancer (NSCLC)source ↗
◆Quarterly UpdateCorporate
Q4 and Full-Year 2025 Financial Results and Pipeline Update Conference Call
▲Full ResultscasdatifanClinical Data
Updated efficacy analysis with DCO January 30, 2026
metastatic clear cell renal cell carcinomasource ↗
◆Topline ReadoutcasdatifanClinical Data
Additional analyses from late-line monotherapy cohorts expected in 1H 2026
late-line ccRCCsource ↗
▲Oral PresentationQuemliclustatPresentation
Data from ARC-9 Phase 2 study of quemliclustat plus gemcitabine/nab-paclitaxel presented at ASCO GI
pancreatic cancersource ↗
◆Trial InitiationAB801Trial
Advancement into expansion cohorts in NSCLC expected in H2 2025
non-small cell lung cancersource ↗
●Enrollment MilestonecasdatifanTrial
Enrollment completion expected for early-line cohorts by end of 2025
early-line ccRCCsource ↗
▲Oral PresentationDomvanalimabDiscontinuedPresentation
OS data from Arm A1 presented at ESMO 2025
upper gastrointestinal adenocarcinomassource ↗
▲Full ResultscasdatifanClinical Data
Pooled analysis of four monotherapy cohorts: mPFS 12.2 months, 18-month landmark PFS 43%
late-line clear cell renal cell carcinoma (ccRCC)source ↗
▲PublicationDomvanalimabDiscontinuedPresentation
EDGE-Gastric data published in Nature Medicine
upper gastrointestinal adenocarcinomassource ↗
▲Partnership / LicensecasdatifanCorporate
Taiho exercised option for exclusive license in Japan and certain Asian territories
clear cell renal cell carcinomasource ↗
◆Oral PresentationPresentation
Fireside chat at Morgan Stanley 23rd Annual Global Healthcare Conference
◆Oral PresentationPresentation
Fireside chat at H.C. Wainwright 27th Annual Global Investment Conference
◆Oral PresentationPresentation
Fireside chat at Citi's 2025 Biotech Back to School Conference
▲Enrollment CompleteQuemliclustatTrial
Enrollment completed for PRISM-1 Phase 3 trial of quemliclustat in first-line metastatic pancreatic ductal adenocarcinoma
first-line metastatic pancreatic ductal adenocarcinomasource ↗
▲Full ResultscasdatifanClinical Data
Prior efficacy and safety analysis with DCO August 15, 2025
metastatic clear cell renal cell carcinomasource ↗
▲Trial InitiationcasdatifanTrial
eVOLVE-RCC02 Phase 1b/3 study initiated
first-line metastatic ccRCCsource ↗
▲Orphan Drug DesignationQuemliclustatDesignation
FDA Orphan Drug Designation granted for quemliclustat
pancreatic cancersource ↗
◆Topline ReadoutcasdatifanClinical Data
More mature data from casdatifan monotherapy cohorts expected
ccRCC (IO-experienced, post anti-PD-1 and TKI)source ↗
▲Enrollment CompleteQuemliclustatTrial
Enrollment completion expected for PRISM-1
first-line metastatic pancreatic ductal adenocarcinomasource ↗
▼Program DiscontinuationEtrumadenantDiscontinuedCorporate
Arcus and Gilead agreed not to pursue Phase 3 for etrumadenant; Gilead returned license
third-line metastatic colorectal cancersource ↗
◆Trial InitiationcasdatifanTrial
Initiation of clinical study evaluating casdatifan plus volrustomig in IO-naive ccRCC
clear cell renal cell carcinoma (ccRCC)source ↗
▲FDA Feedback ReceivedEtrumadenantDiscontinuedFDA Meeting
FDA feedback on registrational path for etrumadenant in third-line mCRC
third-line metastatic colorectal cancer (mCRC)source ↗
▲Oral PresentationcasdatifanPresentation
New clinical data from ARC-20 presented at ASCO GU 2025
clear cell renal cell carcinomasource ↗
▲First Patient DosedQuemliclustatTrial
First patient dosed in Japan by Taiho for PRISM-1 in February 2025
pancreatic cancersource ↗
Past FDA Catalysts and PDUFA Decisions
How RCUS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-30 | Domvanalimab | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
8
Drugs Scored
rNPV / MCap
Top Drug
Top 13%
Small Cap(rank 86 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Quemliclustat Small moleculeNCT06608927 | Metastatic Pancreatic Ductal Adenocarcinoma | Phase 3 | ACTIVE NOT_RECRUITING | 610 | Nov 30, 2030 | ||||||
| casdatifan Small moleculeNCT07011719 | Metastatic Clear Cell Renal Cell Carcinoma | Phase 3 | RECRUITING | 720 | Dec 1, 2030 | ||||||
| casdatifan Small moleculeNCT05536141 | Clear Cell Renal Cell Carcinoma | Phase 1 | RECRUITING | 362 | Mar 1, 2029 | ||||||
| AB598 Small moleculeNCT05891171 | Advanced Cancer | Phase 1 | ACTIVE NOT_RECRUITING | 40 | Sep 1, 2027 | ||||||
| AB102 Small moleculeNCT07662057 | Undisclosed | Phase 1 | RECRUITING | 130 | Dec 1, 2026 | ||||||
| Etrumadenant Small moleculeCompletedNCT03846310 | Non Small Cell Lung Cancer Metastatic | Phase 1 | COMPLETED | 77 | Nov 18, 2024 | ||||||
| Etrumadenant Small moleculeCompletedNCT03629756 | Non-small Cell Lung Cancer | Phase 1 | COMPLETED | 48 | Sep 3, 2021 | ||||||
| Etrumadenant Small moleculeCompletedNCT04381832 | Prostatic Neoplasms, Castration-Resistant | Phase 1 | COMPLETED | 173 | Aug 30, 2024 | ||||||
| Domvanalimab Monoclonal antibodyCompletedNCT05568095 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | Phase 3 | COMPLETED | 1,040 | Aug 28, 2026 | ||||||
| Domvanalimab Monoclonal antibodyCompletedNCT04736173 | Non Small Cell Lung Cancer | Phase 2 | COMPLETED | 320 | Sep 17, 2026 | ||||||
| Domvanalimab Monoclonal antibodyNCT05329766 | Gastrointestinal Tract Malignancies | Phase 2 | COMPLETED | 332 | Sep 7, 2026 | ||||||
| Domvanalimab Monoclonal antibodyCompletedNCT03628677 | Solid Tumor, Unspecified, Adult | Phase 1 | COMPLETED | 75 | Jan 23, 2025 | ||||||
| AB308 Small moleculeCompletedNCT04772989 | Advanced Solid Tumor | Phase 1 | COMPLETED | 94 | Aug 25, 2025 | ||||||
| AB680 Small moleculeCompletedNCT04104672 | Advanced Pancreatic Cancer | Phase 1 | COMPLETED | 196 | Jul 21, 2026 | ||||||
| AB680 Small moleculeCompletedNCT04660812 | Metastatic Colorectal Cancer | Phase 1 | COMPLETED | 227 | Sep 5, 2025 | ||||||
| AB801 Small moleculeCompletedNCT06120075 | Advanced Cancer | Phase 1 | COMPLETED | 29 | Apr 29, 2026 | ||||||
| AB801 Small moleculeCompletedNCT06004921 | Cancer | Phase 1 | COMPLETED | 32 | Feb 23, 2024 | ||||||
| Zimberelimab Monoclonal antibodyMarketedNCT04087018 | Advanced Solid Tumors | Phase 1 | COMPLETED | 18 | Jun 17, 2024 |
Clinical Trial Results
Readouts, endpoints and source filings for every RCUS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| casdatifan | clear cell renal cell carcinoma | 2026-10-20 | first line pfs 12 months: 69%; second line pfs: 14.5 months; late line os: 35 monthsRead More | Arcus Presents New Data from ARC-20 that Demonstrate the Opportunity for Casdatifan to Become a Foundational Treatment Across All Lines of Therapy in Kidney CancerRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Azoy AlexanderOfficer (Chief Accounting Officer) | Option | 2,827 42,408 held | $15.44 | 08/21/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in RCUS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| SOLEUS CAPITAL MANAGEMENT, L.P. | 1.2 % (200 %) | 36.03 M | 1.17 M | 158.58% ( 716.75 K) |
RCUS Institutional Ownership Trends
RCUS Short Interest
Shares sold short, counted twice a month.
14.45%
Short % of Float
of tradable shares sold short
12.4M
Shares Sold Short
-5.7% vs prior count
9.7 High
Days to Cover
trading days of normal volume to buy every short share back
1.3M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How RCUS ranks across every disease it competes in
Competitive Position is a premium feature
See how RCUS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialRCUS News
RCUS▲ +1.4%today
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences announced the granting of stock options to three new employees. A total of 10,650 shares were awarded at an exercise price of $18.54, reflecting the company's commitment to attracting talent. This move supports their focus on developing cancer and immune disease therapies.
Read more →RCUSArcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
Arcus Biosciences announced a public offering of 14,285,715 shares at $17.50 each, aiming to raise $250 million. The offering is expected to close on October 23, 2026, subject to customary conditions. Jefferies and other firms are managing the offering, which follows a previously filed shelf registration with the SEC.
Read more →RCUSArcus Biosciences Announces Commencement of Public Offering of Common Stock
Arcus Biosciences has announced the start of a public offering of its common stock. The offering is fully underwritten by the company and includes a 30-day option for underwriters to buy an additional 15% of shares. The offering is subject to market conditions, with no assurance on completion or terms.
Read more →RCUS▲ +7.3%on this newsshared move
Arcus Presents New Data from ARC-20 that Demonstrate the Opportunity for Casdatifan to Become a Foundational Treatment Across All Lines of Therapy in Kidney Cancer
Arcus Biosciences reported new ARC-20 data showing casdatifan outperformed benchmarks in kidney cancer trials. First-line PFS reached 69% at 12 months, while second-line PFS hit 14.5 months. Late-line monotherapy achieved a 35-month median overall survival. The company plans to start the PEAK-20 Phase 3 trial by year-end.
Read more →RCUSArcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy
Arcus Biosciences is set to host an investor event on October 20, 2026, in New York City. The event will feature new data from the ARC-20 platform study, which evaluates casdatifan as a treatment for kidney cancer across multiple lines of therapy. This highlights the company's commitment to advancing cancer treatment options.
Read more →RCUSArcus Biosciences to Participate in Three Upcoming Investor Conferences
Arcus Biosciences announced its participation in three investor conferences scheduled for September 2026. The management team will engage with investors at these events, highlighting the company's focus on developing differentiated therapies for cancer and autoimmune diseases. This participation reflects the company's commitment to transparency and investor relations.
Read more →RCUSArcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update
Arcus Biosciences reported its financial results for the second quarter of 2026, showcasing a strong performance. The company also provided an update on its clinical pipeline, emphasizing its commitment to developing innovative therapies for cancer and autoimmune diseases. A recent publication in Nature further underscores their research efforts.
Read more →RCUSArcus Biosciences Announces Clinical Supply Agreement with AVEO Oncology to Evaluate Casdatifan in Combination with Tivozanib for Advanced Kidney Cancer Patients
Arcus Biosciences has entered into a clinical supply agreement with AVEO Oncology to assess the efficacy of casdatifan, a small-molecule HIF-2α inhibitor, in combination with tivozanib for patients with advanced kidney cancer. This collaboration aims to explore innovative treatment options for this patient population.
Read more →RCUSArcus Biosciences and Summit Therapeutics Enter Into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer
Arcus Biosciences and Summit Therapeutics have announced a clinical trial collaboration to evaluate the efficacy of casdatifan combined with ivonescimab in treating kidney cancer. This partnership aims to leverage their respective strengths in developing innovative cancer therapies. The trial seeks to address significant unmet medical needs in oncology.
Read more →RCUSArcus Biosciences to Host Conference Call to Discuss Second-Quarter 2026 Financial Results and Pipeline Updates
Arcus Biosciences will hold a conference call on August 5, 2026, to discuss its second-quarter financial results and updates on its drug pipeline. The call is scheduled for 1:30 PM PT / 4:30 PM ET. This event will provide stakeholders with important insights into the company's performance and future directions.
Read more →RCUSNew Research Published in Nature Links Clinical Activity with HIF‑2a Biology in Advanced Kidney Cancer Patients Treated with Casdatifan
A new study published in Nature discusses the relationship between clinical activity and HIF-2a biology in advanced kidney cancer patients treated with Casdatifan. This research may provide insights into the efficacy of Casdatifan in this patient population. Further details about the findings and implications are yet to be disclosed.
Read more →RCUSArcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancer
Arcus Biosciences has announced a clinical trial collaboration and supply agreement to evaluate Casdatifan in combination with a PD-L1/VEGF-A bispecific immunomodulator for treating kidney cancer. This collaboration aims to explore the efficacy of this combination therapy in clinical settings. Further details on the trial design and expected outcomes were not disclosed.
Read more →About Arcus Biosciences, Inc.
Headquarters3928 POINT EDEN WAY, HAYWARD, CA, 94545
BIOPHARMAWATCH ELITE PLUS
Trade the next RCUS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime